Skip to main content
OpenTrials
Completed

NCT Number: NCT03162237

Safety and Efficacy Study of Islets Xenotransplantation

The neonatal pig islets will be used as donor culturing with our modified culture medium. At the same time the autologous T regulatory cells will be used to induce specific immune tolerance for porcine islets grafts combined the costimulation of T cell activation channel blockers. The treatment for type 1 diabetes will be evaluated the efficacy and safety.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cell Transplantation and Gene Therapy Institute

Changsha, Hunan, 410013, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients age 18 to 40 years of age;
  • Type 1 diabetes mellitus for at least 5 years;
  • Body weight 40 to 60kg;
  • Ability to provide written informed consent;
  • Manifest signs and symptoms that are severe enough to be incapacitating;
  • Patients with poor diabetes control (HbA1c > 9% );
  • Patients have diabetes ketoacidosis or hypoglycemia more than once

Exclusion criteria

  • Age < 18 years or > 60 years;
  • Diabetes history < 5 years;
  • Body weight > 80 kg;
  • Exogenous insulin requirement > 1 unit/kg/day;
  • Blood test: hemoglobin male < 90g/l, female < 90 g/l) or Wbc <3×109/L, lymphocyte <1.5×10^9/L; or platelet < 80×10^9/L; activated- partial-thromboplastin-time (APTT) > normal value (31-43s)10s;
  • Liver dysfunction;
  • Kidney dysfunction;
  • Cardiopulmonary dysfunction;
  • Combined mental illness, cancer, infection, severe trauma, pancreatitis, surgery or other stress situations for patients; gastric ulcer patients, any bleeding disorders, tuberculosis infection and active infection including hepatitis B, hepatitis C, HIV, or John Cunningham virus;
  • Serological detection Epstein-Barr virus (EBV) or Cytomegalovirus (CMV)negative;
  • Patient have taken immunosuppressant in recent one year With high incidence of malignancy in three generation;
  • Women not using effective contraception of childbearing age, or planning pregnancy in nearly two years or being pregnant or lactating;
  • Patients can not comply with the research program to complete the diagnosis and treatment;
  • Patients not be passed by Ethics committee

Treatment and study plan

Porcine islets

Other

Porcine islets: 10000IEQ/Kg;

Tacrolimus: 0.087mg/kg, Bid;

mycophemo-latemofetil (MMF): 1g x 2/d;

NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg

Autologous Treg

Other

Autologous Treg: 2x10^6/Kg

Primary outcomes

  1. Blood glucose

    Time frame: 1 year

    Before and after transplantation the patient will be tested the blood glucose. If the blood glucose within 24 hours is stable and no occurrence of diabetic ketoacidosis and hypoglycemia.Thirty percent reduction of exogenous insulin requirement will be considered as effective.

Secondary outcomes

  1. Porcine C-peptide

    Time frame: 1 years

    The patient will be detected the porcine C-peptide levels after transplantion every three months.

  2. Hemoglobin A1c

    Time frame: 1 years

    After transplantation the patient will be checked hemoglobin A1c every month.The level of HbA1c less than 6.5% was considered as effective.

  3. AST

    Time frame: 1 years

    AST will be tested every three months.

  4. ALT

    Time frame: 1 years

    ALT will be tested every three months.

  5. Scr

    Time frame: 1 years

    Scr will be tested every three months.

  6. BUN

    Time frame: 1 years

    BUN will be tested every three months.

  7. Ultrasonic examination for liver

    Time frame: 1 years

    Ultrasonic examination will be used for the recipient's liver before transplantation and every three month post transplantation.

  8. MRI for liver

    Time frame: 1 years

    MRI will be used for liver before transplantaion and every three month post transplantation.

  9. Virus detection

    Time frame: 2 years

    The recipient's serum and peripheral blood monouclear cells (PBMC) will be collected for virus detection every six months.

  10. Immune cells detection

    Time frame: 1 years

    The recipient's peripheral blood monouclear cells (PBMC) and the serum will be collected for immune cell's analysis.

  11. Cytokine detection

    Time frame: 1 years

    The recipient's peripheral blood monouclear cells (PBMC) and the serum will be collected cytokine beads array (CBA) test.

Sponsors and collaborators

Lead sponsor

Wei Wang,MD

Other

Collaborators

  • Hunan Xeno-life Science Ltd

Registry information

Official study title

Investigation of Safety and Efficacy Study of Islets Xenotransplantation for Patients With Type 1 Diabetes

Important dates

Study start
2013
Primary completion
2018
Study completion
2018
First posted
May 22, 2017
Registry last updated
Jun 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.